Table 3.
Antithrombotic Treatment at Discharge.
| CHUM (Selective TATT) N = 66* | CHUS (Ticagrelor-DAPT) N = 101* | Unadjusted p-value | |
|---|---|---|---|
| DAPT | 37 (56%) | 94 (93%) | <0.0001 |
| Clopidogrel | 15 (41%) | 7 (7%) | <0.0001 |
| Ticagrelor | 13 (35%) | 85 (90%) | <0.0001 |
| Prasugrel | 9 (24%) | 2 (2%) | 0.0002 |
| TATT | 29 (44%) | 7 (7%) | <0.0001 |
| Clopidogrel | 24 (83%) | 6 (86%) | 1.0000 |
| Ticagrelor | 1 (3%) | 1 (14%) | 0.3556 |
| Prasugrel | 4 (14%) | 0 (0%) | 0.5658 |
| VKA | 29 (100%) | 7 (100%) | — |
| NOAC | 0 (0%) | 0 (0%) |
*Three CHUM patients and 7 CHUS patients died prior to discharge.
VKA: Vitamin K antagonist; NOAC: Non-vitamin K antagonist oral anticoagulant.